568969788_small  

Alemtuzumab (Lemtrada, Genzyme Corporation/sanofi-aventis) benefits the hardest-to-treat multiple sclerosis (MS) patients, even when the efficacy bar is set at the high possible level, a new study suggests.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()